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Abstract 
Introduction 
Although HIV infection increases the likelihood of developing TB, evidence suggests that 
starting ART reduces the risk of TB incidence although not to the level of HIV negative people 
in the population. This study aims to determine the impact of ART on TB incidence in people 
living with HIV in the Western Cape Province of South Africa. 
Methods 
This is a retrospective cohort study using routinely collected data of HIV infected individuals 
aged 15 years and above from public health facilities in the Western Cape Province, South 
Africa, between 2007 and 2016. A Marginal Structural Model (MSM) with inverse probability of 
treatment weighting (IPTW) was used to estimate the effect of ART on TB incidence adjusting 
for measured time-dependent confounding by CD4 count.  
Results 
ART was associated with a 77.3% (95% CI, 76.7% – 78.0%) reduction in the risk of TB 
incidence in HIV infected patients. The overall TB incidence was 9 855 per 100 000 patient years 
(95% CI, 9 798 – 9 912). Patients on ART and those not on ART had a TB incidence of 3 939 
and 15 329 per 100 000 patient years respectively. TB incidence was higher in males than 
females, and higher in patients with lower CD4 count at baseline and during follow-up. TB 
incidence declined with increasing ART duration and rising CD4 count but remained elevated 
compared to background incidence.  
Conclusion 
This study has shown that ART is highly effective at preventing TB in people living with HIV. 
The recent introduction of universal ART access for everyone living with HIV should contribute 
to further reducing TB incidence in South Africa and other high HIV and TB burden countries.  
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SECTION A: REASEARCH PROTOCOL 
 
The research protocol was written up in 2015-2016 and reflects what was known at that 
time. 
13 | P a g e  
1. Introduction 
1.1 Background 
Tuberculosis (TB) remains a major global health problem and ranks alongside human 
immunodeficiency virus (HIV) as the leading cause of death from communicable diseases 
globally (World Health Organisation, 2015). The latest estimates by the World Health 
Organisation (WHO) states that there were 9.6 million new TB cases and 1.5 million TB deaths 
in 2014 globally. About 1.1 million of the deaths were among HIV negative people and 0.4 
million of the deaths were among HIV positive people (World Health Organisation, 2015). 
These numbers of new cases and deaths are very high, considering that TB is preventable and 
treatable.  
TB remains one of the most frequent opportunistic infections in people living with HIV (Van 
Rie et al., 2011).  Since the early 1980s, the HIV epidemic has led to a major upsurge in TB cases 
and TB mortality in many countries, especially those in Southern and Eastern Africa (World 
Health Organisation, 2014). South Africa is noted to have the highest TB incidence in the world, 
largely resulting from a high population prevalence of HIV infection (Hermans and Manabe, 
2015). The WHO notes that globally people living with HIV are 29 times more likely to develop 
TB disease than those who are HIV-negative (World Health Organisation, 2014). 
Even though HIV has been noted to increase the likelihood that a person will develop TB, 
starting them on antiretroviral treatment (ART) has been seen to reduce their risk of TB 
(Williams and Dye, 2003, Williams, 2013, Edmonds et al., 2009). ART has been noted to be 
highly effective in the reduction of mortality and morbidity and also effective in reducing TB in 
HIV-infected individuals (Van Rie et al., 2011). However, this risk reduction is not to the level of 
HIV negative people. Various studies have shown risk reductions ranging from about 60% to 
80% in TB incidence in patients receiving ART (Santoro-Lopes et al., 2002, Miranda et al., 2007, 
Golub et al., 2007, Golub et al., 2009, Lawn et al., 2010, Suthar et al., 2012).  
High incidence of TB in the first months of ART have been consistently documented across 
different regions globally (Van Rie et al., 2011, Moore et al., 2007, Girardi et al., 2005, Lawn et 
al., 2005, Bonnet et al., 2006, Brinkhof et al., 2007, Dembele et al., 2010, Rajasekaran et al., 
2009). This is in part a result of the unmasking of subclinical TB during the initial rapid 
restoration of the immune response (Lawn et al., 2009). The incidence of TB declines the longer 
patients are on ART in most of the cohorts investigated (Moore et al., 2007, Girardi et al., 2005, 
Lawn et al., 2005, Brinkhof et al., 2007, Lawn et al., 2009).  However, this incidence remains 
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higher than the background TB incidence in the general population, even after years of being on 
ART (Lawn et al., 2009, Gupta et al., 2012, Gupta et al., 2015). This elevated long-term TB 
incidence has been shown to be strongly associated with the time spent at CD4 count <500 
cells/mm3. A CD4 threshold of 350 cells/ µL has been noted as the best predictor which 
determines whether ART increases or decreases TB incidence in the long term (Williams, 2013).  
Starting ART very late and low coverage of ART has been noted to increases population level 
incidence of TB, however, HIV positive people on ART are expected to live longer and have an 
elevated risk of TB infection for a much longer time as they remain alive (Williams, 2013). Thus, 
in the course of HIV infection, starting ART very late increases the lifetime risk of TB, while 
starting ART very early decreases the lifetime risk of TB. 
Many longitudinal clinical studies  have treatment or exposure variables and other time-varying 
covariates that change over time and are measured several times during the study (Daniel et al., 
2013). The estimation of the causal effect of ART on TB incidence in patients living with HIV 
depends on the time-varying confounders that also affect the outcome, and in most cases 
standard methods give biased estimates of the causal effect in the presence of these time-varying 
confounders (Hernan et al., 2000). Thus, there is need to control specifically for time-
confounding in these types of studies. In looking at the impact of ART on people living with 
HIV on TB incidence, there is time-varying confounding which occurs when confounders have 
values that change over time, and an example of this is CD4 count (Hernan et al., 2000, Hernan 
et al., 2002). Thus, estimating the overall causal effect of a time-varying exposure (ART) would 
need adjustment of the time-varying confounders (Robins et al., 2000, Hernan et al., 2000). 
The double burden of the HIV and TB burden in South Africa has created operational 
challenges to the health system that has traditionally run vertical programmes for HIV and TB, 
with treatment delivered by healthcare staff, most often located in separated facilities (Kaplan et 
al., 2014). The vertical model of delivering HIV and TB care to co-infected patients in South 
Africa relied upon referral and linkage to care between the two programmes. This creates 
challenges and inefficiencies in referrals between the two, as referrals depend on patients’ 
resources and health care seeking behaviour which is mostly unmonitored, which in turn results 
in poor treatment outcomes in patients co-infected with TB and HIV needing access to both 
services (Kaplan et al., 2014).  
TB ascertainment also remains a challenge as there is a lack of robust point-of-care tools for 
diagnosis in these high HIV prevalence settings (Haraka et al., 2015, World Health Organisation, 
2015). In most cases TB diagnosis relies on radiological findings, microscopy, clinical symptoms 
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and culture which is not routinely done due to lack of capacity and infrastructure (Parsons et al., 
2011, Haraka et al., 2015, World Health Organisation, 2015). In addition there is no evidence-
based tool to screen for TB in people living with HIV that is universally accepted 
(Padmapriyadarsini et al., 2011). 
1.2 Motivation 
There is a paucity of information on TB incidence in HIV patients on ART in high burden HIV 
settings including South Africa. Understanding the incidence of TB and associated risk factors 
over time in patients who are on ART is crucial for effective service planning and intervention 
strategies. Data on the incidence of TB at different levels of CD4 count is also lacking, and these 
data, if available, would assist in informing models of TB burden as the ART program matures. 
Thus, the purpose for undertaking this research is to provide insight into the impact of ART on 
TB incidence.  
1.3 Aims and Objectives 
1.3.1 Aims 
The aim of the study is to investigate the impact of ART on TB in HIV positive patients 
attending public health facilities in the Western Cape Province.  
1.3.2 Objectives 
The objectives of the study are: 
• To describe TB incidence in patients co-infected with HIV 
• To describe temporal trends in TB incidence in patients with HIV 
• To describe TB incidence by CD4 count stratum pre-ART 
• To describe TB incidence by CD4 count stratum post-ART 
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2. Methods  
2.1 Study Design 
A retrospective cohort study of HIV patients between 2007 and 2016 in the Western Cape 
Province will be conducted. The retrospective cohort study will allow the description of the HIV 
population over time and measures of association with TB (risk ratio, odds ratio, hazard ratio)  
(Mann, 2003, Doll, 2001). The study design is justified as it would not be feasible to accrue 
sufficient patient numbers prospectively, and, exposures and outcomes can be adequately 
identified retrospectively from the patient level data.  
2.2 Population and Sampling 
The study population will be a cohort of adult HIV infected patients attending public health 
facilities in the Western Cape Province, with HIV status first evidence ascertained between 2007 
and 2016. Prior to 2007 the data was incomplete as most of the information systems in the 
province were mostly paper based. The patients must be free of TB disease at HIV first evidence 
ascertainment. We will extract an anonymous data set of HIV patients and linked TB events, 
with HIV treatment start dates, TB outcomes and treatment completion dates, all CD4 counts, 
age and gender. Thus a priori sample size of all available HIV patients aged 15 and above and TB 
events in the province is going to be derived. This should be adequately powered for precise 
estimates of event rates and the causal effect of ART, given the large number of HIV and TB 
patients in the Province. First evidence of HIV and TB is based on laboratory diagnosis, HIV 
and TB electronic registers, pharmacy data and hospital diagnostic codes.  
2.3 Inclusion criteria 
• HIV positive patients aged 15 years and above, with HIV first evidence ascertained 
between 2007 and 2016 
• Patients must be free of TB at HIV first evidence 
• Patients must not be on ART at HIV first evidence 
2.4 Key variables  
Cohorts will be described by year of HIV first evidence, ART status, age, gender, TB events, TB 
disease classification, CD4 counts and co-infection with TB pre and post ART.  
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2.5 Outcomes 
The primary outcome in the study will be the incidence of TB in HIV patients. Incident TB will 
be defined as the first episode of TB between 2007 and 2016. The incidence of TB will be 
examined pre and post ART exposure. 
3. Data sources and analysis  
3.1 Data management  
Patient registration system in the Western Cape have evolved to an extent that the same unique 
patient health identifier is used across source electronic patient systems including hospitals, 
community health centres and clinics (Western Cape Department of Health, 2013). This unique 
patient identifier issued by the hospital information system (Clinicom), referred to as the  patient 
master index (PMI) (also called folder number or clinicom number) has created new 
opportunities to assemble and link individual patient level data across multiple source systems, 
including laboratory data (NHLS), pharmacy data (JAC), chronic disease dispensing  data (CDU) 
and disease management systems for TB and HIV ( TIER.Net, EKAPA [electronic HIV 
registers], ETR and EDR [electronic TB registers for drug sensitive and drug-resistant TB 
respectively]) (Western Cape Department of Health, 2013).  
 
The province has a near complete disease management information systems for HIV and TB 
treatment (Western Cape Department of Health, 2013). Data on HIV and TB patients is 
routinely collected at health facilities where the patients come regularly for their treatment in the 
province. Selected patient information critical to programme monitoring is recorded and collated 
into the centralised electronic HIV and TB databases. The province through the Data Centre at 
the Health Impact Assessment Unit is proactively curating and integrating this individual patient 
level data from all the different source systems, linking this data on the PMI from the multiple 
source systems into a master patient list. All the data used is anonymised for analysis using an 
internal unique identifier which is used when releasing the anonymised patient level data. 
 
Data will be checked and corrected for any inconsistencies, which include age, gender, HIV and 
TB first evidence dates and ART start dates. Patients with TB prior to HIV will be removed 
from further analysis. The data will be managed, cleaned and analysed in STATA 15 (StataCorp, 
2017).  
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3.2 Statistical Analysis 
• Descriptive statistics will be employed to summarise the characteristics of the HIV and 
HIV-TB co-infected population in the province.  
• TB incidence will be estimated by gender, age groups, year of HIV first evidence, CD4 
count stratum at baseline and CD4 count stratum time-varying in patients who have 
started and have not started ART using the Cox proportional hazards model. 
• Kaplan-Meier estimates and curves will be used to describe patients who have started 
and who have not started ART by gender, age groups, year of HIV first evidence, CD4 
count stratum at baseline and time-varying CD4 count stratum. 
• To adjust for time-varying confounding, the Cox proportional hazards marginal structural 
model (MSM) is going to be used to estimate the effect of HIV treatment on the outcomes. 
This will include the following steps: 
1. Estimate each subject’s probability of being treated (treatment weights) each time 
(monthly), using logistic regression adjusted for baseline and time-varying 
covariates  
2. Estimate each subject’s probability of being censored (censoring weights) each 
time (monthly), using logistic regression adjusted for baseline and time-varying 
covariates 
3. Use the treatment and censoring weights to derive the inverse probability of 
treatment weights 
a. IPTW is defined as the inverse of each subject’s probability of his or her 
treatment history at each time 
b. Weights may need to be truncated if extreme 
4. Fit a weighted Cox model (approximated by a pooled logistic regression model 
across all times) for the causal effect of treatment, controlling for baseline 
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4 Ethics 
4.1 Ethics approval 
Ethics approval for this proposed study will be obtained from the University of Cape Town 
Health Research Ethics Committee (UCT-HREC). In addition, approval will be obtained from 
the Western Cape Government Department of Health in order to conduct the study using the 
routine health data. Ethical principles stated in the Declaration of Helsinki 2013 developed by 
the World Medical Association(World Medical Association, 2013) will be adhered to. 
4.2 Subjects confidentiality 
All the patient information will be kept strictly confidential (only anonymised data will be 
received by the researcher) and the analysis will be conducted on anonymised data to ensure that 
no personal identifying information is used. In addition, the database will be stored on a secure 
computer, secured with a password to limit access. Should the study be published, there will be 
no identifying data, as anonymised data will be used, thus confidentiality of the patients will be 
maintained. 
4.3 Risks and benefits Potential risk 
The data to be used in the study has not been collected specifically for research study purposes 
but rather routinely. Hence there are no risks involved in the analysis of this data. The findings 
hopefully are going to provide information on the impact of ART on the incidence of TB for 
different HIV patients. This will be useful in devising TB control strategies and interventions in 
HIV patients on treatment in the country. This study does not carry any direct harm or risk to 
the general wellbeing of the patients. The study is not going to offer any monetary 
reimbursement or any direct benefits to the patients. 
 4.4 Dissemination and presentation of research findings 
The analysis will be prepared for the partial fulfilment of the requirements of the Master of 
Public Health dissertation to the University of Cape Town, Department of Public Health and 
Family Medicine. Results and findings will be shared with and presented to the Western Cape 
Government Department of Health, who are the custodians of health data in the province, and 
other key stakeholders including the University of Cape Town School of Public Health and 
Family Medicine. It is hoped this will assist them in devising strategies and interventions which 
will improve health outcomes of HIV patients. An article will be submitted to a peer reviewed 
medical journal and abstracts will be submitted to conferences for presentation of findings.  
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4.5 Conflict of interest statement 
No conflicts of interest exist in this study. 
5 Budget 
This dataset is pre-existing and thus no overhead costs are expected and no funding to analyse 
these data is required. 
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1.1 Introduction 
There is a dual epidemic of Tuberculosis (TB) and human immuno-deficiency virus (HIV), 
posing a major threat to global public health with the interaction between the two escalating the 
burden of disease and death in many populations (Harries et al., 2010, Suthar et al., 2012b). HIV 
infection is the strongest risk factor for developing TB disease and it is fuelling its resurgence, as 
well as the risk of death during TB treatment (Corbett et al., 2003, Harries et al., 2010). TB is the 
commonest acquired immune-deficiency syndrome (AIDS) defining condition globally (Moreno 
et al., 2008). TB is also endemic in the HIV negative population (Corbett et al., 2003) in many 
high HIV-burden countries. Antiretroviral treatment (ART) has been shown to reduce the 
impact of HIV on TB incidence, with risk of TB being reduced in previous studies by 65% 
(Suthar et al., 2012).  
1.2 Objectives 
This literature review seeks to appraise and summarise published articles on: 
• Burden of HIV, TB and HIV and TB co-morbidity 
• ART treatment and coverage 
• TB incidence in HIV patients on and not on ART 
1.3 Methodology 
1.3.1 Search strategy 
A systematic literature review was conducted using the PICO strategy to identify literature 
regarding TB incidence in HIV patients, either on ART or not on ART. PubMed online database 
and google scholar  were used to search for relevant articles using a combination of search terms 
that include ‘tb incidence’, ‘HIV’, ‘ART’,’ antiretroviral therapy ‘,’adults’, ‘burden’. Search was restricted 
to English language articles only, with no time restriction. A periodic search for new articles for 
this review was conducted between October 2016 and July 2018, with articles included as 
appropriate after review. Abstracts and titles of resulting articles were reviewed, with further 
follow up and review on related articles shown in PubMed. Articles were included in the review 
if they were relevant to the study objectives. 
The search strategy aimed to identify and include studies reporting on the burden of disease of 
HIV and TB, TB incidence in HIV patients either on treatment or not, impact of ART on TB 
incidence, ART coverage. An effort was made to be systematic and thorough in finding all the 
prior studies estimating the impact of ART on TB, without formally seeking to conduct a 
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systematic review, which would be beyond the scope of this dissertation.  Articles on children 
under the age of 15 were excluded from the review. 
1.4 Burden of TB 
1.4.1 Global burden of TB 
TB remains a global health threat and is the leading cause of morbidity and mortality 
(Churchyard et al., 2014, Raviglione and Sulis, 2016, World Health Organization, 2017, Floyd et 
al., 2018). Globally, 10.4 million people are estimated to have been infected with TB in 2016 with 
6.3 million  of these TB cases reported to the WHO (World Health Organization, 2017). An 
estimated 90% of these TB cases were adults, 65% were male and 10% of them were living with 
HIV. South-East Asia Region had 45% of the incident cases, with 25% from the African Region, 
17% from Western Pacific Region with smaller proportions of cases occurring in Eastern 
Mediterranean Region (7%), European Region (3%) and American Region (3%) (World Health 
Organization, 2017).  
Two-thirds of the cases are mainly from seven countries, namely India, Indonesia, China, 
Philippines, Pakistan, South Africa and Nigeria.  The WHO notes that TB is endemic in most of 
these developing countries due to weak health and surveillance systems, under-diagnosis and 
underreporting of cases (World Health Organisation, 2015). Results from the global burden of 
disease study of 2015 focusing on the global burden of TB showed lower estimates of TB 
incidence and deaths globally but similar trends regionally, although these lower estimates are 
due to different computational methods used (Kyu et al., 2018).  
Despite progress being made in reduction of TB mortality, TB is the ninth leading cause of death 
worldwide and the leading cause from a single infectious agent (World Health Organization, 
2017, Floyd et al., 2018, Kyu et al., 2018). There were 1.3 million TB deaths among HIV negative 
people and an additional 374 000 deaths among HIV positive people in 2016 (World Health 
Organization, 2017). Africa had 25% of the TB related deaths occurring in the region.  
1.4.2 Burden of TB in South Africa 
Chaisson and Martinson (2008) state that Africa is facing the worst TB epidemic since the advent 
of the antibiotic era and it is largely driven by a generalized HIV epidemic. They note that this 
has been compounded by weak health care systems, inadequate laboratories, and conditions that 
promote transmission of infection (Chaisson and Martinson, 2008). TB is also noted to be 
mostly concentrated in Southern Africa where most of the countries in this region apart from 
South Africa have poor vital registration and incomplete notification systems (Kyu et al., 2018)  
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South Africa has been noted to have one of the world’s worst TB epidemics driven by HIV and 
accounts for about 4% of the global incident cases (Churchyard et al., 2014, World Health 
Organization, 2017). South Africa had an estimated  incidence of 781 TB cases per 100 000 
population in 2016 (World Health Organization, 2017). Churchyard et al (2014) highlight South 
Africa to have the highest estimates of TB incidence and prevalence, the second highest number 
of diagnosed multidrug-resistant TB cases, and the largest number of HIV-associated TB cases.  
TB incidence trends by province in South Africa have shown consistent declines in recent years, 
despite incidence in all of them being above 250 per 100 000 population, the level declared to be 
a health emergency by the WHO (National Iinstitute for Communicable Diseases, 2017). In 
2015, the province with the highest incidence was Eastern Cape with 865 cases per 100 000 
population, more than three times  the lowest incidence of 251 cases per 100 000 in Limpopo 
(National Iinstitute for Communicable Diseases, 2017). The Western Cape Province had an 
incidence of 625 per 100 000 people in 2015, a decline from 980 in 2004 (National Iinstitute for 
Communicable Diseases, 2017).  
1.5 Burden of HIV and treatment 
1.5.1 Global burden of HIV 
Despite the remarkable progress that has been made in curbing the HIV/AIDS epidemic 
worldwide, the number of people living with HIV/AIDS has been increasing, from 2.4 million in 
1985 to 36.9 million in 2017, with disparate levels and trends of the epidemic at country level 
(Wang et al., 2016, UNAIDS, 2017, UNAIDS, 2018). HIV-related mortality has been declining 
since the mid-2000s due to the introduction of antiretroviral therapy (ART) (UNAIDS, 2017). 
However, annual incidence has stayed relatively constant since 2005, after a period of faster 
decline prior to 2005 (Wang et al., 2016). UNAIDS state that new infections have been reduced 
by almost half, from a peak in 1996 of about 3.4 million new infections to about 1.8 million new 
infections in 2017 (UNAIDS, 2018).  
More than two thirds of all people living with HIV globally knew their HIV status in 2017, and 
of those who knew their HIV status 79% are noted to be accessing ART (UNAIDS, 2018). More 
than half of all people living with HIV (59%) are estimated to be on treatment, and this is due to 
the global scale-up of ART, with the number of people on ART more than doubling, from an 
estimate of about 8 million in 2010  to about 21.7 million in 2017 ( (UNAIDS, 2018). 51% of the 
people living with HIV globally are women, and they are noted to have a higher treatment 
coverage and better adherence to treatment than men (UNAIDS, 2017). The increase in people 
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on ART was greater for women, 3.3% to 42.4%, than men, 6.4% to 38.6%, between 2005 and 
2016 (Wang et al., 2016). There has been an increase in the number of people starting treatment 
globally each year over time, from about 564 000 in 2005 to around  2.4 million in 2016 
(UNAIDS, 2017). 
Sub-Saharan Africa is the most profoundly affected region in the world by the HIV epidemic, 
with 75.4% of infections in 2015, and 6 countries from Southern Africa having a prevalence 
above 10% (Wang et al., 2016). 19.6 million people in Eastern and Southern Africa are estimated 
to be living with HIV in 2016, which is more than half of the people living with HIV globally  
(Williams and Dye, 2003). Despite the high numbers of people living with HIV in these regions, 
Eastern and Southern Africa have made huge strides in getting people to start ART early (Wang 
et al., 2016). In people living with HIV in Eastern and Southern Africa at the end of 2017, 81% 
of the people were aware of their HIV status with about 66% of the people on treatment 
(UNAIDS, 2018). 
 
The 12.9 million people on ART in Eastern and Southern Africa in 2017 represented an almost 
threefold increase over 2010 numbers, translated into a coverage increase from 23% to 66% 
between 2010 and 2016 (UNAIDS, 2017, UNAIDS, 2018). UNAIDS noted that treatment 
coverage was highest in Botswana at 83% and Rwanda at 80%, but several countries with large 
populations of people living with HIV (Ethiopia [59%], South Africa [56%] and Mozambique 
[54%]), reported coverage below the regional average. 
1.5.2 HIV burden in South Africa  
In South Africa, the number of people living with HIV has increased from an estimated 4.94 
million in 2002 to 7.06 million in 2017, an increase of about 43% (Statistics South Africa, 2017). 
The HIV prevalence in the total population increased  from 10.9% in 2002 to 12.6% in 2017 
(Statistics South Africa, 2017). The prevalence in the country is slightly higher in adults between 
the ages of 15 and 49, with an estimated prevalence of 18% (peak in the 25-34 age group) in 
2017, in comparison to the other ages (Western Cape Provincial AIDS Council, 2016, Statistics 
South Africa, 2017). Prevalence  in the 15-49 ages was estimated to be higher in women (21.3%) 
than men (18%) in 2017  (Statistics South Africa, 2017). The increase in the national ART roll-
out since its inception in 2005 has resulted in a decline in AIDS related deaths,  reversed 
historical patterns of increasing mortality, and has extended the lifespan of many people in the 
country (Statistics South Africa, 2017). In 2017, 4.4 million people were estimated to be on ART 
in South Africa, the largest treatment programme in the world (UNAIDS, 2016, UNAIDS, 
30 | P a g e  
2018). UNAIDS estimates 61% of people living with HIV to be on ART in the country in 2017, 
with more adult women  (66%) compared to adult men (53%)  living with HIV on ART 
(UNAIDS, 2018). 
1.5.3 HIV burden in the Western Cape Province 
In the Western Cape Province, the number of people living with HIV are estimated to have 
increased from 269 259 to 430 491 between 2007 and 2016, with the number of new infections 
decreasing from 28 615 to 19 396 in the same period (Johnson et al., 2017). The prevalence of 
HIV in the province is estimated to have slightly increased from 5.0% to 6.6% between 2007 and 
2016, the lowest in the country (Shisana et al., 2014, Johnson et al., 2017). The number of 
patients on ART are noted to have increased from 32 100 (28 453 for patients aged 15+) in 2007 
to 216 025 (208 631 for patients aged 15+)  in 2016 (Johnson et al., 2017). The 2015 Western 
Cape sero-prevalence HIV Antenatal Survey estimated an HIV prevalence of 18.9%  in the 
Western Cape Province among the participants, the lowest in the country (Department of 
Health, 2017). The participants are expectant mothers; thus, they are expected to have a higher 
prevalence than the average population as new mothers are, by definition, a sexually active sector 
of the population not using barrier methods of contraception. 
1.5.4 Treatment regimens for HIV  
WHO guidelines for initiating ART have evolved over the past 10 to 15 years. In 2002, ART 
was firstly recommended for HIV infected patients in moderate and advanced stages of 
infection to limit disease progression to mortality (World Health Organization, 2002, Plazy et 
al., 2015) whilst others recommended that ART would be more effective if initiated earlier and 
before advanced HIV disease (Walensky et al., 2009, Grinsztejn et al., 2014). The WHO 
expanded their recommendations in 2006, which were further reinforced in 2010 with 
recommendations for ART initiation for HIV patients with CD4 counts lower than 350 
cells/μL, when most people are asymptomatic (World Health Organization, 2006, World 
Health Organization, 2010, Plazy et al., 2015).  The WHO guidelines in 2013 suggested an 
expansion of the ART eligibility criteria at CD4 counts  less than 500 cells/μL (World Health 
Organization, 2013). In addition to the clinical benefits, the expanded eligibility was also 
premised on the potential to reduce transmission. This was based on findings showing that 
ART lowered viral load in HIV infected individuals and significantly decreased the risk of HIV 
transmission within sero-discordant couples (Attia et al., 2009, Cohen et al., 2011). 
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Prior to 2010 in South Africa, the eligibility for ART in adults included a CD4 count a CD4 cell 
count ≤ 200 cells/µl , or an AIDS-defining diagnosis (excluding extra-pulmonary TB)  (Stinson 
et al., 2017). These guidelines were then changed in 2010 to a CD4 threshold of < 350 cells/µl 
for pregnant women and people with TB. These were further changed in 2013 to include 
patients with a CD4 cell count < 350 cells/µl, all patients with TB and pregnant women 
irrespective of CD4 count. Further revisions were implemented in 2015 for the provision of 
ART for all HIV-infected adults with a CD4 cell count ≤ 500 cells/µl.  
1.5.5 History of ART in South Africa 
South Africa has been rolling out ART  for more than 15 years, and the country has the largest 
number of people living with HIV and has the largest ART programme globally, with over 3.8 
million people estimated to be on treatment as of 2016 (Massyn et al., 2016, Johnson et al., 
2017). During the first decade of care, South African ART guidelines lagged behind those 
stipulated by the WHO regarding ART eligibility due to political resistance to ART rollout 
(Nattrass, 2006, Chigwedere et al., 2008), but in 2011 were brought in line with 2010 WHO 
recommendations for the first time (Bekker et al., 2014, Plazy et al., 2015). Since coming into line 
with WHO ART guidelines in 2010, and the announcement of a comprehensive care, 
management and treatment programme by the Department of Health in late 2003, access to 
ART in SA has increased dramatically with many more patients being enrolled into treatment.  
It is estimated that 86% of HIV positive adults had been diagnosed in the country in 2015, with 
little variation between the nine provinces (Johnson et al., 2017). The diagnosed adults, 57% 
were reported to be on ART, with variation between the provinces, from  51% in North West 
Province to 73% in the Northern Cape Province (Johnson et al., 2017). The authors noted that 
overall ART coverage varied from 43% in Gauteng to 62% in Northern Cape Province. 
Meanwhile the South African National HIV prevalence, incidence and behaviour survey 
estimates ART among people living with HIV to have doubled from 16.6% in 2008 to 31.2% in 
2012 (Shisana et al., 2014). They also noted a significant difference between the proportion of 
men (25.7%) and women (34.7%) on ART, a finding that is due to gender differences in health 
seeking behaviour as well as the fact that all pregnant women access antenatal care and are tested 
for HIV, and thus higher rates of ascertainment for women accessing antenatal care  facilitating 
them into treatment (Shisana et al., 2014). The National Department of Health in 2013 noted 
that the rapid scale-up of ART services in the country resulted in a four-fold increase in the 
number of people receiving ART between 2009 and 2012 (Department of Health, 2014). 
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In 2016, South Africa implemented the WHO evidence based guidelines of Universal Test and 
Treat (UTT), a faster strategy towards attaining the global 90-90-90 targets by 2020 (Department 
of Health, 2016, Massyn et al., 2016). These guidelines are based on evidence that early initiation 
on ART results in better clinical outcomes than delayed treatment (Massyn et al., 2016). The 
global 90-90-90 target, were set by UNAIDS to achieve 90% rate of diagnosis in HIV positive 
individuals, to provide ART to 90% of diagnosed individuals and to achieve virological 
suppression in 90% of ART patients (UNAIDS, 2014). Despite 3.8 million people on ART in 
South Africa, it is estimated that the program is only reaching 53% of those who are eligible for 
treatment under the new test and treat policy in the country (SANAC, 2017).  
1.6 Dynamics of HIV/TB co-infection 
1.6.1 Global HIV/TB co-infection 
Globally TB and HIV are the biggest threats to public health (Suthar et al., 2012b).  
In 2016, 1.4 million (13%) new TB cases were amongst people living with HIV worldwide 
(World Health Organization, 2017). WHO also estimated 1.3 million TB deaths among HIV 
negative people and 374 000 deaths among HIV positive people worldwide in 2016. TB is the 
main cause of mortality and morbidity in people living with HIV and is the most common cause 
of death in HIV positive adults, and the greatest burden is in sub-Saharan Africa due to the 
generalized HIV epidemic, especially in Southern Africa where more than 50% of new 
tuberculosis cases are co-infected with HIV (Corbett et al., 2003, Harries et al., 2010, Rangaka et 
al., 2014, World Health Organization, 2017).  
1.6.2 Risk of HIV/TB co-infection 
In a number of different settings, the risk of TB has been demonstrated to be higher in HIV-
infected patients. HIV infection is the strongest risk factor for TB and has fuelled its resurgence 
(Corbett et al., 2003, Harries et al., 2010). WHO (2017) state that HIV-positive people are 20 to 
30 times more likely to develop TB disease than HIV-negative people. HIV is noted to be one of 
the major driving forces for the persisting TB epidemic in Sub-Saharan Africa, and a strong 
correlation between HIV prevalence  and an elevated risk of TB incidence  has been observed in 
the region (Musa et al., 2015). Various studies conducted in different countries of differing HIV 
prevalence have also shown this strong correlation. In a 28-year retrospective cohort study in 
Israel, they noted an elevated risk of TB incidence in people living with HIV, more especially 
those originating from high HIV and TB prevalence countries as compared to the locals (Mor et 
al., 2013).  In another study in England, Wales and Northern Ireland, people living with HIV 
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originating from sub-Saharan Africa also had higher elevated risk of TB incidence, with 80% of 
them having HIV and  TB co-infection (Zenner et al., 2015).  
1.6.3 HIV/TB co-infection in South Africa 
In the African region, where the burden of HIV associated TB is highest,  74% of the new TB 
cases were among people living with HIV and 40% of deaths among HIV-positive people were 
due to TB  (World Health Organization, 2017). South Africa has the largest HIV and one of the 
largest TB epidemics in the world (Evans, 2013, Massyn et al., 2016, Western Cape Provincial 
AIDS Council, 2016, Abdool Karim et al., 2009). As of 2017, 60% of people with TB were noted 
to be living with HIV in the country.  
 
HIV being the key driver of the TB epidemic, the proportion of TB patients who know their 
HIV status increased considerably from 43.3% in 2008 to 94.8% in 2015 in the country (Massyn 
et al., 2016). This shows that a high proportion of TB patients know their HIV status in the 
country. For the Western Cape, the proportion of TB patients knowing their HIV status is 
estimated to be 96.1%, which is the highest in the country.  
 
In 2015, the average TB and HIV co-infection across South Africa was 56.7% (Massyn et al., 
2016). TB patients in Gauteng, Mpumalanga and KwaZulu-Natal had the highest co-infection at 
68.4%, 68.1% and 63.6%, respectively. The Eastern Cape, Northern Cape and Western Cape had 
far lower HIV co-infection at 45.2%, 41.1% and 38.5%, respectively. According to the 2014 
World Health Organization Global TB Report, 62% of all TB cases in South Africa are co-
infected with HIV and only 66% of these received antiretroviral therapy (ART) during TB 
treatment (World Health Organisation, 2014). 
 
South Africa currently has the largest antiretroviral programme in the world, which will expand 
even more as the new policy of universal testing and treating continues to be rolled out (Massyn 
et al., 2016).  It is important that TB patients are aware of their HIV status so that if they are 
dually infected with TB and HIV, antiretroviral treatment (ART) can be started immediately. In 
the country, the number of co-infected patients on antiretroviral therapy (ART) increased from 
28.0% in 2011 to 84.5% in 2015. ART coverage in the general population is lower than in 
patients co-infected with HIV and TB, and is estimated to be 59.1% in 2016 and increase from 
6.4% in 2007 (Johnson et al., 2017). The Western Cape had the lowest proportion of co-infected 
patients on ART of  75.7% in 2016 which is higher than the ART coverage in the general 
population of 53% in the same year (Massyn et al., 2016, Johnson et al., 2017) . 
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For many years, TB and HIV care were largely separate, however robust efforts have been made 
to tackle them simultaneously.  The integration of TB and HIV services have been mandated in 
the National Strategic Plan, South African National AIDs council (SANAC) and National TB 
Programme to ensure that co-infected patients receive appropriate care and treatment 
(Department of Health, 2014, SANAC, 2017). The policy has stated the need for integration 
through co-location of the HIV and TB services nationwide. Various initiatives have been 
implemented since 2012 which include proactive diagnosis of TB among people living with HIV 
using GeneXpert, integrated HIV/TB services for people in the mining industry, correctional 
facilities, communities surrounding gold mines and informal settlements, collection and 
improvements in information’s systems on HIV/TB. 
1.7 TB incidence in HIV patients on ART 
In this section we systematically reviewed the studies estimating TB incidence and associations 
between ART and TB incidence in HIV-infected patients.  We have included studies on TB 
incidence and the impact of ART, as study objectives cover both. Tables 1 to 3 summarise 
studies describing the impact of ART on TB incidence in people living with HIV. They include 
the setting where the study was conducted, methods used, sample size, key findings and 
summary of the results. We have included studies from developed countries to show the 
disparities when compared to South Africa. 
1.7.1 Characteristics of studies 
Forty studies met the inclusion criteria on TB incidence and associations between ART and TB 
incidence in HIV infected patients, with 15 of the studies from developed countries, and 25 from 
developing countries (10 from South Africa). Table 1 to 3 describes the characteristics of the 
included studies conducted in developed countries, developing countries and South Africa 
respectively.  
1.7.2 Study designs, sample sizes and calendar periods 
Thirty-eight of the studies were cohort studies (retrospective and prospective), while the 
remaining two studies were a systematic review and meta-analysis of 11 cohort studies and a 
meta-analysis of 9 cohort studies respectively. The studies had follow-up periods ranging from 1 
to 14 years. Sample sizes of studies conducted in developed countries ranged from 165 to 
65 121, and the studies included events between 1980 and 2015. Sample sizes of studies 
conducted in developing countries ranged from 219 to 67 686, with events from 2003 to 2014. 
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Sample sizes of studies conducted in South Africa ranged from 264 to 74 074, with events from 
1992 to 2016.  
Of the 40 studies, 21 studies estimated the association between ART and TB incidence, 10 from 
developed countries, 5 from developing countries excluding South Africa and 6 from South 
Africa. Of the 21 studies, 10 studies (5 of these in the developed countries, 4 in developing 
countries and 1 in South Africa) estimated the impact of ART on TB incidence with adjustment 
for baseline and time-varying covariates using conventional methods, and 4 studies (3 of these in 
the developed countries, one in South Africa) used causal analysis to adjust for time-varying 
confounding. Of the 19 which did not estimate the impact of ART on TB incidence, 5 are from 
developed countries, 10 from developing countries excluding South Africa and 4 from South 
Africa. These only estimated TB incidence, and other associations with incidence. 
1.7.3 Results from studies 
The studies reported results either as measures of association (hazard ratios, risk ratios, odds 
ratios) or as incidence, with some reporting both.  In this section we are going to highlight 
studies with measures of association that had adjustment for time-varying confounding. For 
these studies the impact of ART in reduction of TB incidence ranged from 32% to 80%.  
In the systematic review and meta-analysis of 11 studies in developing countries by Suther et al 
(2012), ART was associated with a 65% reduction in TB incidence. They also estimated TB 
incidence reduction at all CD4 count stratum of 84%, 66% and 57% for CD4 count <200, CD4 
count between 200 and 350 and CD4 count >350 respectively. The meta-analysis of 9 cohort 
studies by Lawn et al (2010), ART was associated with a 67% reduction in TB incidence. 
In studies conducted in the developed countries using conventional methods, there were small 
and substantial reductions in TB incidence associated with ART observed. Jones et al (2000) and 
Santoro-Lopez et al (2002) estimated an 80% reduction in TB incidence. Moreno et al (2008), 
Muga et al (2007) and Golub et al (2007), estimated reduction in TB incidence of 74%, 69% and 
59% respectively. While in studies that used causal analysis, there were reductions of 73%, 44% 
and 32% estimated by Huang et al (2015), del Armo et al (2012) and Petit et al (2011) 
respectively.  
Two studies conducted in the developing countries by Lawn et al (2010) and Yirdaw et al (2014) 
and estimated reduction of TB incidence due to ART of 67% and 68% respectively using 
conventional methods. While Ayele et al (2015) estimated the reduction in the combined effect 
of ART and IPT of 60%. In studies from South Africa, Golub et al (2009) estimated a significant 
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impact of ART on TB incidence reduction of 64%, while Bachman et al (2015) estimated a low 
reduction of 33% adjusting for time-varying covariates. While in the only study to adjust for 
time-varying confounding in South Africa, Fairall et al (2008) estimated a 39% reduction in TB 
incidence. 
In the 10 studies that used conventional methods, adjusting for the covariates was more likely to 
accentuate rather than attenuate the effect of ART on TB incidence, while in the 4 studies with 
adjustments for time-varying confounding ( 3 from developed countries and 1 from south 




37 | P a g e  
Table 1: Summary of included studies global /developed countries 
Authors, year setting Study design and 
methods 
Population and sample 
seize 
Impact of ART 
estimated 
Key findings HR (95% CI) /incidence (95% CI) 
(Huang et al., 
2015) 





models adjusted for 
baseline and time-
varying covariates. 
6 897 Adult HIV patients 
aged 18+ followed up 
between December 2003 and 
February 2014 
Yes ART associated with 73% reduction in TB 
incidence 
-Unweighted model, no covariates:  
HR 0.34 (95% CI, 0.26-0.43) 
-Unweighted model, baseline and time-varying 
covariates:  
HR 0.29 (95% CI, 0.21-0.38) 
-Weighted model, baseline covariates: 
HR 0.27 (95% CI, 0.19-0.37) 
(del Amo et al., 
2012) 
12 cohorts from 
High income 
countries (United 







65 121 HIV positive, ART 
naïve, AIDS free adults ≥18 
years followed up between 
1996 and 2007 
 
 
Yes -ART associated with a 44% reduction in 
TB incidence in patients who initiate ART 
 
-Unweighted model, baseline covariates 
HR 0.81 (95% CI, 0.67 - 0.97) 
-Unweighted model, baseline and time-varying 
covariates:  
HR 1.03 (95% CI, 0.86-1.24) 
-Weighted model, baseline covariates: 
HR 0.56, (95% CI, 0.44-0.72) 
(Miranda et al., 
2007) 
 HIV treatment 





-463 HIV positive adults aged 
18+ followed up between 1 
January 1995 and 31 
December 2001 
Yes -HAART associated with an 80% reduction 
in TB incidence 
HR 0.2 (95% CI, 0.1- 0.6)  
(Golub et al., 
2007) 
29 Public clinics, 






11 026 HIV positive patients, 
between 1 September 2003 
and 1 September 2005 
Yes -ART associated with a 59% reduction in 
TB incidence 
-Adjusted HR 
0.41 (95%CI, 0.31 – 0.54) 
-Unadjusted HR 
0.55 (95%CI, 0.45 – 0.68) 
(Girardi et al., 
2000) 






2 160 HIV positive adult 
patients aged 18+, between 1 
May 1995 and 30 April 1996 
Yes -ART significantly reduced the risk of TB, 
with ART associated with a 92% reduction 
in TB incidence 
-Adjusted HR triple ART combination 
0.08 (95% CI, 0.01 – 0.88) 
-Adjusted HR double ART combination 
0.16 (95% CI, 0.03 – 0.74) 
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(Santoro-Lopes et 
al., 2002) 




255 HIV positive patients, 
between January 1991 and 
December 1994 
Yes -Use of ART reduced incidence of TB in 
high HIV prevalence areas 
-ART associated with an 80% reduction in 
TB incidence  
-Adjusted HR 
0.2 (95%CI, 0.04 – 1.13) 
 
(Muga et al., 
2007) 





2 238 HIV positive patients, 
between 1980 and 2004 
Yes -ART associated with a 69% reduction in 
TB incidence 
-HR 
0.31 (95%CI, 0.17 – 0.54) 
 
(Jones et al., 2000) 100 clinics and 





Between January 1996 and 
June 1998 
Yes -The use of HAART reduced the risk of 
TB, with a risk reduction of 80% 
-adjusted RR 
0.2 (95% CI, 0.1 – 0.5) 
(Pettit et al., 2011) Care centre 
Nashville, TN 





-4 534 HIV positive adult 
patients followed up between 
January 1998 and December 
2008. 
Yes -TB incidence declines with duration on 
HAART in this low TB incidence setting. 
-HAART associated with a 32% reduction 
in TB incidence in the first 180 days since 
initiation, and a 90% reduction after 180 
days initiation 
-Weighted model, baseline covariates <180 
days since HAART initiation: 
HR 0.68 (95% CI, 0.14–3.22) 
-Weighted model, baseline covariates>180 days 
since HAART initiation: 
HR 0.10 (95% CI, 0.04–0.31) 





based cohort study 
-Poisson regression  
4 268 patients followed up 
between 1 January 1997 and 
31 December 2003.  
Yes -HAART was associated with 74% risk 
reduction in the incidence of TB 
-HAART associated with lower TB rates 
-Women had lower TB rates than men 
-adjusted RR  
0.26 (95% CI, 0.16–0.40) 
-unadjusted RR 
 0.39 (95% CI, 0.21–0.70) 
(Girardi et al., 
2005) 
12 cohorts from 
Europe and North 
America 




12 cohorts with sample size of 
17 142 treatment naïve HIV 
patients between 1996 and 
2003.  
No Use of HAART reduces TB incidence -TB incidence rate  
4.69, (95% CI, 3.99-5.39) per 1 000 pyrs 
- TB incidence rate males  
4.3 per 1 000 person-years 
- TB incidence rate females  
5.8 per 1 000 person-years 
(Lannoy et al., 
2008) 
7 Health centres in 
Brasilia Federal 





-281 HIV positive adults, 
ART naive, AIDS program 
Health Department of Brasilia 
in 1998, followed up for 60 
No -Non-use of ART was independently 
associated with increased risk of TB 
-TB incidence rate  
1.24 (95% CI, 0.66-2.12) per 100-person years 
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months between January 1998 
and December 2003 
(Zenner et al., 
2015) 
England, Wales and 




hazard regression  
44 050 HIV adult patients 
aged 15+ between 2000 and 
2008 linked to the national 
TB register and death register 
No Incidence of TB among HIV-diagnosed 
persons remained very high in the first 6 
months after HIV diagnoses.  
-Cumulative TB incidence rate  
2.13 per 100 person-years  
-7.2% of the HIV individuals developed TB 






165 HIV/AIDS patients aged 
18 and older on ART for at 
least six months followed up 
between January 2013 and 
December 2015. 
No High incidence of TB observed, and the 
incidence of TB was significantly associated 
with biological failure. 
8.5% of the patients developed TB within 2 
years 
(Mor et al., 2013) National HIV and 





6 579 HIV patients between 
1983 and 2010 
No -TB incidence declined with duration on 
ART 
-ART associated with reduction in TB 
incidence  
-Overall TB incidence rate 
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Table 2: Summary of included studies Africa/developing countries 
Authors, year setting Study design and 
methods 
Population and sample 
seize 
Impact of ART 
estimated 
Key findings HR (95% CI) /incident rates (95% CI) 








67 686 HIV-positive adults 
(age 15+) enrolled in the HIV 
care and treatment program 
between November 2004 and 
September 2012 
Yes -ART associated with a 72% reduction in 
TB incidence after 36months on ART 
-TB incidence lower for patients on ART 
compared to those not on ART 
-TB incidence declined with increasing 
duration on ART. 
-Male patients and a 53%higher risk of 
TB than females 
-HR (36+ months on ART time-varying)  
0.28 (95% CI, 0.25-0.33) 
- Males versus females HR 
1.53, 95% CI, 1.45-1.60 
-TB incidence rate ART naïve patients 
 7.9 (95% CI, 7.6–8.2) per 100 person-years   
-TB incidence rate for patients on ART 
4.4 (95% CI, 4.2-4.4) per 100 person-years  
(Suthar et al., 
2012a) 












cohort studies, and 
retrospective cohort 
studies comparing TB 
incidence by ART 
status in HIV-infected 
adults 
11 studies namely 
-4 from sub-Saharan Africa, 
- 4 from South America, 
-1 from Caribbean,  
-1 from Asia  
-1 from combination of sub-
Saharan Africa, South 
America, and Asia 
Yes -ART associated with a 65% reduction in 
TB incidence 
-ART strongly associated with a reduction 
in TB incidence across all CD4 count 
categories. 
- CD4 count<200 cells/µl  
HR 0.16, (95% CI, 0.07- 0.36) 
- 200<CD4 count< 350 cells/µl  
HR 0.34, (95% CI, 0.19 - 0.60) 
- CD4 count> 350 cells/µl  
HR 0.43, (95% CI, 0.30 - 0.63) 
- Any level of CD4 count  
HR 0.35, (95% CI, 0.28 - 0.44) 
(Yirdaw et al., 
2014) 
Electronic database 
of patients under 
care at 5 HIV/ART 





5 407 HIV-positive patients 
enrolled into HIV care 
between September 2007 and 
August 2010 
Yes ART associated with 68% reduction in 
TB incidence 
-adjusted HR:  
0.32, (95%CI, 0.24-0.43) 
-unadjusted HR:  
0.74, (95%CI, 0.58-0.96) 
 
(Lawn et al., 2010) Limited resource 
settings 
-9 Cohort studies 
-Meta-analysis  
37 879 HIV-positive adults 
aged 18+ 
Yes -ART associated with a 67% reduction in 
TB incidence 
-Adjusted HR 
0.33 (95%CI, 0.27 – 0.39) 
(Ayele et al., 2015) Dilla University 






- 1 922 adult HIV-positive 
patients aged 15+ enrolled in 
chronic care between 2007 
and 2013 
Yes 60% reduction in TB incidence due to the 
combined effect of IPT and ART  
Combined effect of ART an IPT- 
-Unadjusted HR 0.35, (95% CI, 0.16 -0.77) 
-Adjusted HR 0.40 (95% CI, 0.18-0.87) 
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(Chang et al., 2015) Electronic clinical 










-50 320 HIV-positive adults 
enrolled and followed up 
between May 2005 and 
February 2012 
No -TB incidence decreased with longer 
duration on ART  
-Overall TB incidence rate 
 25.8 (95% CI, 24.7-27.0) cases per 1 000 
person-years 
-6.2% of the patients developed TB after ART 
initiation 








-400 HIV-positive adult 
patients aged 15+ initiating 
ART between 1 September 
2007 and 30th of August 
2008. 
No -High incidence of TB after initiating 
ART within the first year 
-Early ART initiation beneficial in 
reducing TB incidence  
-TB incidence rate 
2.2 (95% CI, 0.94 - 5.09) per 100 person-years 
(Hermans et al., 
2010) 




5 982 HIV-infected adults 
initiating ART between 




No - Reduction in TB incidence with 
duration on ART  
-Incidence TB very high within first 3 
months of ART initiation, especially in 
patients with very low CD4 counts 
 
-TB incidence in the first 2 years  
  3.14 (95% CI, 2.82-3.49) per 100 person-years  
-TB incidents rates at 
  0-3 months 11.25 (95% CI, 9.58-13.21), 
  3-6 months 6.27 (95% CI ,4.99-7.87), 
  6-12 months 2.47 (95% CI, 1.87-3.36)  
  12-24 months and 1.02 (95% CI, 0.80-1.31) 
-OR after 2 years on ART 
   2.02 (95%CI, 1.13 – 3.59) 
-HR CD4 count <50  
   1.84 (95% CI, 1.25 – 2.70)  






-2 596 HIV-positive adults 
aged 15+ initiating ART 
between 2004 and 2007 
 
  
No -Patients with lower CD4 counts had 
higher TB incidence rates compared to 
patients with higher CD4 count 
-High TB incidence among patients 
observed 
TB incidence rate 
2.32 (95% CI, 1.80 – 3.05) per 100 person-years 
(Akanbi et al., 
2013) 




5 093 HIV-positive adults 
aged 18+ on ART for at least 
a year between January 2006 
and March 2011 
No -TB incidence higher in patients with 
lower CD4 count 
-73% reduction in TB incidence 
associated with ART between the first 
and fourth year after starting 
-TB incidence rate  
8.72 (95% CI, 7.15 – 10.63) per 1 000 person-
years. 
-HR in CD4 count>≥350 versus CD4 count 
<350 after first year of ART 
0.47 (95% CI, 0.28 – 0.77) 
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(Worodria et al., 
2011) 




-219 HIV-positive patients 
aged ≥18 initiating ART, 
followed up for a year 
No -Incidence of ART associated TB noted 
to be relatively low in this setting of high 
HIV and TB prevalence 
-TB incidence rate (ART associated) 
4.3 per 100 person-years 








-8 374 HIV-positive adult 
patients pre and post ART 
aged 16+ followed up 
between 1 January 2010 to 1 
February 2013  
No -Extremely high TB incidence observed 
-Significant difference incidence of TB 
before and after ART initiation 
-TB incidence rate pre-ART 
31.7 (95% CI, 29.8 – 33.7) per 100 person-years 
-TB incidence rate on-ART 
11.4 (95% CI, 10.4 – 12.4) per 100 person-years 






-4 210 HIV-positive adult 
patients aged 15+receiving 
HAART between September 
2005 and October 2009 
No -use of HAART reduces TB incidence  
-Reduction in TB incidence with duration 
on ART 
-TB incidence rate 
3.1 (95% CI, 2.58–3.62) per 100 person-years  
-TB incidence in first year 
3.3 (95% CI, 1.17 – 5.43) per 100 person-years 
-TB incidence in 5 years  
 0.4 (95% CI, 0.21 – 0.59) per 100 person-years  







345 HIV-positive adults aged 
≥18 years followed up for 10 
years between March 2004 
and April 2014 
No -Reduction in TB incidence across all 
CD4 counts 








cohort study  
-Cox proportional 
hazard model 
3496 adult HIV patients on 
ART aged≥ 15 years between 
January 2004 and December 
2012 
No -TB incidence significantly higher in 
patients with lower CD4 count compared 
to patients with higher CD4 count 
-low TB incidence after ART initiation 
-TB incidence rate  
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Table 3: Summary of included studies, South Africa 
Authors, year setting Study design and 
methods 
Population and sample 
seize 
Impact of ART 
estimated 
Key findings HR (95% CI) /incident rates (95% CI) 





-2 423 HIV-positive adults 
aged 18 starting ART, 
followed up between January 
2014 and 30 May 2016 
Yes -73% reduction in TB incidence 
associated with ART among patients with 
CD4 count greater than 500 when 
compared with patients with CD4 count 
less than 500 
-Adjusted HR (CD4>500 versus CD4 ≤500) 
0.27 (95% CI, 0.12-0.62)  
-TB incidence per 100 person-years 
4.41 (95% CI, 3.62-5.39) overall 
9.62 (95%CI, 7.27-12.73) CD4 <200 
3.15 (95%CI, 2.05-4.83) 201<CD4 <350 
3.85 (95%CI, 2.51-5.91) 351<CD4 <500 
1.26 (95%CI, 0.57-2.81) CD4 >500 
(Kufa et al., 2016) 2 Clinics, Gauteng 
Province, South 
Africa 
-Prospective cohort  
-Cox proportional 
hazards regression 
-634 HIV-positive patients 
aged 18 to 45 years with CD4 
counts > 350 cells/μl 
followed up between June 
2011 and June 2012  
 
 
Yes -32% reduction in TB incidence 
associated with ART in patients with CD4 
count greater than 350 
-TB incidence high in these patients with 
high CD4 count greater than 350 
-adjusted HR 0.68 (95 % CI, 0.18 – 1.82) 
-unadjusted HR 0.65 (95 % CI, 0.24-1.81) 
-Overall TB incidence  
2.7 (95 % CI, 1.6 - 4.4) per 100 person-years  
-on ART TB incidence rate  
2.2 (95 % CI, 1.0 – 4.5) per 100 person-years  
-no ART TB incidence rate  
3.4 (95 % CI, 1.6 – 7.0) person-years  
-TB incidence per 100 person-years 
2.4 (95%CI, 1.2-4.8) CD4 >500 
3.3 (95%CI, 1.5-7.3) 350<CD4 <500 









74 074 HIV-positive adult 
patients aged 16+ followed up 
between May 2004 and June 
2010  
Yes -ART associated with a 33% reduction in 
TB incidence  
-Reduction in TB incidence with longer 
duration on ART 
-ART effective in preventing TB in 
patients with low CD4 count 
(<350 cells/μl) 
-adjusted HR 
0.67 (95% CI, 0.64 – 0.70) 
-unadjusted HR 
0.64 (95% CI, 0.57-0.71) 
-TB incidence on ART 
4.9 per 100 person-years  
-TB incidence not on ART 
9.0 per 100 person-years 
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(Golub et al., 
2009) 






2 778HIV-positive adults aged 
18+, between 1 June 2003 and 
31 December 2007 
Yes -ART associated with a 64% reduction in 
TB incidence 
-High incidence of TB in this population  
-Adjusted HR 
0.36 (95%CI, 0.25 – 0.51) 
-Unadjusted HR 
0.62 (95%CI, 0.44 – 0.87) 
(Badri et al., 2002) Somerset Hospital 
adult HIV clinic, 
South Africa 





-264 HIV patients in clinical 
trial on HAART and 770 non-
HAART patients in cohort 
followed up between 1992 
and 2001 
Yes -HAART associated with an 80% 
reduction in TB incidence 
-HAART has a protective effect on TB 
incidence in HIV patients 
-adjusted RR  
0.19 (95% CI, 0.9 – 0.38) 
-TB incidence on HAART 
2.4 per 100 person-years 
-TB incidence rate not on HAART 
9.7 per 100 person-years 
(Fairall et al., 
2008) 
 







-14 267 HIV-positive patients 
aged 16+, followed up 
between 3 May 2004 and 31 
December 2005 
 
Yes -HAART associated with an 39% 
reduction in TB incidence 
 
-Unweighted model, no covariates:  
HR 2.4 (95% CI, 2.1-2.7) 
-Unweighted model, baseline and time-varying 
covariates: HR 0.69 (95% CI, 0.54-0.89) 
-Weighted model, baseline covariates: 
HR 0.61 (95% CI, 0.46 – 0.81) 
 
 








7 536 HIV-positive patients 
initiating ART between 1 
April 2004 and 31 March 2008 
No -Severity of HIV disease associated with 
TB incidence 
-Very high TB incidence in the first few 
months on ART 
-TB incidence rate of TB on ART  
 4.2 (95% CI, 3.8 – 4.5) per 100 person-years 
 - TB incidence rate in first 3 months on ART  
21.7 (95% CI, 17.5 - 26.7) per 100 person-years 






1 480 HIV-positive patients 
initiating ART between 
September 2002 and March 
2006 
No -TB incidence rates are very high, and 
they decline with an increase in CD4 
count 
-TB incidence rate per 100 person-years 
7.28 (95%CI, 6.32 – 8.36) overall 
16.76 (95%CI, 12.76:21.62) CD4 <100 
9.27 (95%CI, 7.15:11.82) 101<CD4 <200 
5.48 (95%CI, 3.88:7.52) CD4 201<CD4 <300 
4.61 (95%CI, 2.92:6.91) CD4 301<CD4 <400 
4.23 (95%CI, 2.25:7.24) CD4 401<CD4 <500 
1.50 (95%CI, 0.49:3.49) CD4 >500 
 
(Fenner et al., 
2017) 
3 treatment 
programmes (2 in 
-Retrospective cohort 
study 
-44 260 HIV-positive adult 
patients aged 16+ starting 
No -Early ART initiation and retention on 
ART 
-TB incidence rate 
45 | P a g e  








ART between 1 January 2000 
and 31 December 2014 at 
three ART programmes 
-Reduction in TB incidence with increase 
in CD4 count on patients on ART 
 26.2 (95% CI, 25.3–27.0) per 1 000 person-
years.  
(Gupta et al., 
2012) 






-1 544 HIV-positive adults 
aged 16+ on ART between 
September 2002 and May 
2006 
No -Reduction of TB incidence with longer 
duration on ART 
-ART effective in preventing TB in 
patient with low CD4 count 
(<350 cells/μl) 
-TB rates higher than in uninfected 
population regardless of duration on ART 
or high CD4 count 
-TB incidence rate during ART 
 7.44 (95% CI, 6.80 – 8.13) per 100 person-
years  
-TB incidence rate first year of ART 
12.4 (95% CI, 10.8 – 14.4) per 100 person-years 
-TB incidence rate between 5-8 years on ART 
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1.7.4 Conclusion (TB incidence and effect of ART) 
Most of the studies reviewed were retrospective and prospective cohort studies. These studies 
vary in terms of sample sizes, settings as a well as the range of results. Despite the variations in 
study design, size and population most of the studies have shown a reduction in TB incidence 
due to ART in people living with HIV, with reductions ranging between 32% and 92%. 
Variation in the results of the included studies could be due to the different study settings and 
different sample sizes used as well as the different methods applied.  
 
Most of the studies used the Cox regression to model the effect of ART on TB incidence with 
traditional adjustments to the estimates, while only a few used causal methods of analysis to 
derive the adjusted estimates. Of the studies which used causal methods between the different 
settings, adjusting for time-varying confounding resulted in modest further accentuation of the 
estimate of the effect of ART. In South Africa there is only one study by Fairall et al (2008) that 
used causal methods, conducted early on in the scale-up of ART in the Free State Province, and 
they had an estimate of 39% reduction in TB incidence due to ART. 
1.8 Conclusion 
In this review, we have described the burden TB as well as the burden and treatment of HIV. 
We have also given a brief description of the dynamics of HIV and TB co-infection and further 
described the impact of ART in TB incidence in people living with HIV. We have found that TB 
cases are higher in high HIV prevalence settings in the developing countries particularly in sub-
Saharan Africa. We have also identified HIV as the driving force for the high TB incidence in 
these settings. ART roll-out which is increasing at different paces in the different regions globally 
is noted to be having an important impact in the reduction of TB incidence. There have been 
relatively few robust studies in the Southern African context quantifying this impact, using 
appropriate methods, and including more recent calendar periods. 
This study is an opportunity to determine the impact of ART on TB incidence in our high TB 
and HIV prevalence setting. Very few studies have been conducted at such a population wide 
level with high levels of outcome ascertainment in patients attending public health sector. The 
level of patient detail also allows us to adjust for time-varying confounding, which has rarely 
been done in our setting. The knowledge generated will contribute to the body of literature on 
the impact of ART on TB incidence in people living with HIV in our settings.  
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Abstract 
Introduction 
Although HIV infection increases the likelihood of developing TB, evidence suggests that 
starting ART reduces the risk of TB incidence although not to the level of HIV negative people 
in the population. This study aims to determine the impact of ART on TB incidence in people 
living with HIV in the Western Cape Province of South Africa. 
Methods 
This is a retrospective cohort study using routinely collected data of HIV infected individuals 
aged 15 years and above from public health facilities in the Western Cape Province, South 
Africa, between 2007 and 2016. A Marginal Structural Model (MSM) with inverse probability of 
treatment weighting (IPTW) was used to estimate the effect of ART on TB incidence adjusting 
for measured time-dependent confounding by CD4 count.  
Results 
ART was associated with a 77.3% (95% CI, 76.7% – 78.0%) reduction in the risk of TB 
incidence in HIV infected patients. The overall TB incidence was 9 855 per 100 000 patient years 
(95% CI, 9 798 – 9 912). Patients on ART and those not on ART had a TB incidence of 3 939 
and 15 329 per 100 000 patient years respectively. TB incidence was higher in males than 
females, and higher in patients with lower CD4 count at baseline and during follow-up. TB 
incidence declined with increasing ART duration and rising CD4 count but remained elevated 
compared to background incidence.  
Conclusion 
This study has shown that ART is highly effective at preventing TB in people living with HIV. 
The recent introduction of universal ART access for everyone living with HIV should contribute 






56 | P a g e  
Introduction 
Background 
The double burden of the human immunodeficiency virus (HIV) and tuberculosis (TB) epidemic 
and co-infection makes them the biggest threat to public health worldwide (Suthar et al., 2012b, 
Massyn et al., 2016). TB remains one of the most frequent opportunistic infections in people 
living with the HIV (Van Rie et al., 2011). The World Health Organisation (WHO) notes that 
people living with HIV are 16 to 27 times more likely to develop TB disease than those who are 
HIV negative. Since the early 1980s, the HIV epidemic has led to a major upsurge in TB cases 
and TB mortality in many countries, especially those in Southern and Eastern Africa (World 
Health Organisation, 2014).  
TB is the main cause of mortality and morbidity in people living with HIV/AIDS, especially in 
low-income countries (Harries et al., 2010). The greatest burden is in sub-Saharan Africa due to 
the generalized HIV epidemic (World Health Organization, 2017). South Africa is noted to have 
the highest TB incidence in the world, largely resulting from a high population prevalence of 
HIV infection (Hermans and Manabe, 2015). 
Although being infected with HIV infection increases the likelihood that a person will develop 
TB, starting them on antiretroviral treatment (ART) has been seen to reduce their risk of TB 
(Williams and Dye, 2003, Williams, 2013, Edmonds et al., 2009). This risk reduction, however, is 
not completely to the same risk for HIV negative people  (Williams, 2013).  A study looking at 
TB in patients receiving ART found an 80% reduction in TB incidence  (Van Rie et al., 2011). 
This study also highlighted that the ART program had revolutionized the care of HIV-infected 
individuals as evidenced by dramatic reductions in morbidity and mortality. 
HIV positive people on ART are expected to live longer than those without treatment, and thus 
have an elevated risk of TB infection over their much longer life span (Williams, 2013).  Hence, 
this could lead to an increase in the population level incidence of TB. Starting ART very late 
after infection and low coverage of ART also increases the population level incidence of TB 
(Williams, 2013). Thus, in the course of HIV infection, starting ART very late increases the 
lifetime risk of TB, while starting ART very early decreases the lifetime risk of TB. 
ART outcomes in a non-randomised setting are noted to be biased by confounding by indication 
(Edmonds et al., 2009). Estimating the impact of ART on TB is complicated by time-varying 
confounding, and standard epidemiological methods for effect estimation are inadequate in the 
presence of these time-dependent confounders (Robins et al., 2000). Essentially patients with 
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more advanced HIV disease are more likely to be started on ART, and the same patients are also 
likely to develop TB, usually resulting in under-estimation of the true impact of ART on HIV-
associated TB incidence if the statistical methods do not explicitly adjust for time-varying 
confounding. 
There is a paucity of information on TB incidence in HIV patients on ART globally as well as in 
the country. Operational challenges to the health system in South Africa have been created due 
the HIV and TB programmes being run vertically, with treatment  for each delivered in different 
facilities (Kaplan et al., 2014). This relies on referral and linkage to care between two vertical 
programmes, which is often suboptimal, and complicates tracking patients between services, and 
ascertaining TB diagnosis in cohorts of HIV patients. 
Understanding the incidence of TB and associated risk factors over time in patients with HIV 
and who are on ART is crucial for developing effective intervention strategies. Data on the 
incidence of TB by CD4 count and ART status are lacking and are required to inform models of 
TB burden as the ART program matures, more especially with the 90-90-90 targets. This study 
analyses data from a large cohort of patients with HIV, pre and post-ART in those who receive 
ART, attending public health facilities in the Western Cape Province of South Africa. The 
primary objective of this study was to describe the impact of ART on TB incidence in patients 
living with HIV, controlling for time-varying confounding. Secondary objectives were to provide 
robust estimates of TB case-finding by CD4 count and ART status. 
Methods 
Study design and setting 
This is a retrospective cohort study using routinely collected data of HIV infected adults aged 
above the age of 15 attending public health facilities in the Western Cape Province, South Africa. 
The study period was between 2007 and 2016. The retrospective study allowed the description of 
the HIV cohort over time, event rates and measures of associating with TB (hazard ratios).   
Population and sampling 
The study population was a cohort of adult HIV infected patients attending public health 
facilities in the Western Cape Province, with HIV status ascertained between 2007 and 2016. An 
anonymous data set of all the HIV cohort linked to TB events was extracted.  
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Inclusion criteria  
We included patients aged 15 years and above with HIV first evidence between 2007 and 2016. 
The patients had to be free of TB at HIV first evidence, and not be on ART at HIV first 
evidence.  
Data source and management 
The patient registration system in the Western Cape has evolved to an extent that the same 
unique patient health identifier is being used across source electronic patient systems across 
hospitals, community health centre and clinic records is being used(Western Cape Department 
of Health, 2013). This unique patient identifier issued by the hospital information system 
(Clinicom), referred to as the  patient master index (PMI) (also called folder number or Clinicom 
number) has created new opportunities to assemble and link individual patient level data across 
multiple health information source systems, including laboratory data (critical in the diagnosis of 
TB), pharmacy data, chronic disease data and disease management systems for TB and HIV 
(Western Cape Department of Health, 2013).  
 
The province has a near complete disease management information system for HIV and TB 
treatment (Western Cape Department of Health, 2013). Data from HIV and TB patients is 
routinely collected at health facilities where the patients come regularly for their treatment in the 
province. All the patient information is recorded and collated into the centralised electronic HIV 
and TB databases. The Provincial Health Department, through the Provincial Health Data 
Centre (PHDC), is proactively curating and integrating this individual patient-level data from 
different source systems, linking the data to the PMI. All data is anonymised prior to the analysis 
by assignment of unique identifiers valid only for this anonymised dataset. Data was checked and 
corrected for any inconsistencies, which included age, gender, HIV and TB first evidence dates 
and ART start dates.  
Key variables and outcomes 
The primary outcome was defined as the first evidence of TB pre and post initiation of ART, 
with incident TB defined as the first episode of TB between 2007 and 2016. Potential 
associations with TB included demographic variables (age and gender), ART start date (ART 
status), CD4 counts (baseline and time-varying) and year of HIV first evidence. First evidence of 
HIV and TB is based on laboratory diagnosis, HIV and TB electronic register, pharmacy data 
and hospital diagnostic codes. Mortality of the patients was ascertained through evidence 
available from the hospital information systems as well as death registration from the 
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Department of Home Affairs which was only available between 2011 and 2013. Thus, mortality 
was not considered a viable and robust outcome, as hospital information systems only record 
deaths that occur in provincial facilities.  
Statistical methods and analysis 
Statistical analysis was performed using Stata version 15 (StataCorp, 2017).  Standard descriptive 
statistics were used to characterize the cohort. Time to TB case diagnosis was described with 
Kaplan-Meier estimates and curves. 
Standard epidemiological methods for effect estimation are inadequate in the presence of time-
dependent confounders that are themselves affected by previous exposure (Robins et al., 2000). . 
Thus, the Marginal Structural Model (MSM) with inverse probability of treatment weighting 
(IPTW) was used to estimate the effect of ART on TB incidence adjusting for measured time-
dependent confounding by CD4 count (Robins et al., 2000, Fewell et al., 2004). CD4 count is 
associated with both the probability of treatment (ART) and the outcome (TB incidence). The 
study entry was shifted 3 months forward (lagged) for some analyses, due to HIV and TB co-
diagnosis and patients presenting with TB testing positive with HIV. Analysis was done on the 
full and lagged datasets. CD4 counts (time-varying) were only carried forward for a year if no 
further results were available, in keeping with clinical guidance on repeat CD4 count testing pre-
ART (the study predated universal ART provision). No imputation was done for patients with 
missing baseline or follow-up CD4 counts.  
Analysis was done at the person month level, with multiple records per patient in the MSM. 
Baseline covariates used were age, gender, baseline CD4 count and year of HIV first evidence, 
while CD4 count was used as the time-varying covariate. Stabilised inverse probability treatment 
weights were estimated using two logistic regression models. The first model (numerator 
weights) had ART as the outcome and baseline covariates, restricted cubic splines and months of 
follow-up as the independent variables, while the second model (denominator weights) had ART 
as the outcome and baseline covariates, time-varying covariates (CD4), restricted cubic splines  
for time and months of follow-up as the independent variables. Stabilised inverse probability of 
censoring weights was also estimated using the two logistic models, but with censoring as the 
outcome.  
The treatment and censoring weights were then combined to estimate the stabilised IPTW. We 
truncated the stabilised IPTW at the 0.5% and 99.5% percentile based on recommendations of 
truncating very large weights to ensure a mean weight of 1  (Cole and Hernan, 2008). The mean 
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weights of the truncated IPTW models were 1.03 and 1.05 for the lagged and full models 
respectively (supplementary Table 4).  
Presented models included the unweighted unadjusted model (representing the crude association 
between ART and TB incidence), the model adjusted for baseline co-variates (representing 
traditional adjustment of this association by baseline co-variates), and the model including 
adjustment for baseline co-variates and additionally including the IPTW’s (the causal estimate 
accounting for time-varying confounding by CD4 count). 
Ethical considerations 
This study was approved by the University of Cape Town Research Ethics Committee (reference 
number UCT-HREC 759-2016) and the Western Cape Government, Department of Health, 
Health Research Committee. Ethical principles stated in the Declaration of Helsinki 2013 
developed by the World Medical Association (World Medical Association, 2013) were adhered 
to. The data extracted was anonymised to keep all patient information confidential. 
Results 
A total of 494 871 HIV patients linked to 115 374 TB patients met the inclusion criteria in the 
full data set and 441 310 HIV patients linked to 61 813 TB patients in the lagged dataset 
excluding patients with potential simultaneous diagnoses of HIV and TB (Figure1). In the final 
analysis cohort (Table 1), 65% of the HIV patients were female, compared to 55% of TB 
patients being female (supplementary Table 2). The median age at HIV-first evidence was 31.0 
years (IQR, 25.6-38.1, 29.2 for females and 34.3 for males, Table 1 and supplementary Figure 4). 
The median age at TB first evidence was 32.7 years (IQR, 27.0 – 39.6, 30.4 for females and 35.3 
for males, supplementary Table 2 and supplementary Figure 4).  The median CD4 count at HIV 
first evidence was 324 (IQR,182-499), while the median CD4 count at ART start was 242 (IQR, 
151-347). A total of 193 727 (39.1%) HIV patients had ever started ART. At baseline, 8.8% of 
the patients had a missing CD4 count.  
TB incidence 
The overall TB incidence was 9 855 per 100 000 patient years (95% CI, 9 798 – 9 912) in the full 
dataset and 5 835 per 100 000 patient years (95% CI, 5 7888 – 5 881) in the lagged dataset. The 
TB incidence in patients on ART (Table 1 and supplementary Figure 4) was 3 939 per 100 000 
patient years (95% CI, 3 888 – 3 992), while the TB incidence in patients not on ART was 15 329 
per 100 000 patient years (95% CI, 15 231 – 15 427) in the full dataset. In the lagged dataset, the 
TB incidence in patients on ART was 3 645 per 100 000 patient years (95% CI, 3 595 – 3 696), 
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while the TB incidence in patients not on ART was 8 144 per 100 000 patient years (95% CI, 8 
066 – 8 222). 
The male TB incidence of 16 460 per 100 000 patient years (95% CI, 16 320 – 16 602) was over 
double the female TB incidence of 7 398 per 100 000 patient years (95% CI, 7 341 – 7 456) in 
the full dataset, while in the lagged dataset the male TB incidence of 8 297 per 100 000 patient 
years (95% CI, 8 191 – 8 404) was about 1.7 times greater than the female TB incidence of 4 948 
per 100 000 patient years (95% CI, 4 898 – 4 997). TB incidence increased with a decrease in 
CD4 count in patients on and off ART in both the full and lagged datasets. TB incidence also 
increased with an increase in age and year of HIV first evidence. During the ten-year follow-up 
period, 39 234 patients were known to have died (7.9%), with 17 399 and 21 835 dying before 
and after starting ART respectively. 
The Kaplan-Meier (K-M) failure curve in Figure 2 (A and B) showed patients on ART having 
lower probabilities of TB incidence than patients not on ART, in both the full and lagged 
dataset. Males had a higher probability than females of TB incidence (supplementary Figure 6 (A 
and B)). We observed that many of HIV and TB diagnoses were made simultaneously, resulting 
in a prominent peak in TB incidence within the first few months of HIV diagnosis in the full 
dataset.  
Comparison of baseline and time-varying CD4 count K-M failure curves showed higher 
probabilities of TB incidence in patients with lower CD4 counts compared to patients with 
higher CD4 counts (Figure 2 (C and D) and Figure 7 (A and B)), with patients on ART having 
lower failure probabilities compared to those not on ART. Comparison of CD4 count categories 
showed higher risk of TB incidence in patients not on ART compared to patients on ART in all 
strata (Table 1). Older age groups were also more at risk of TB than younger age-groups 
regardless of ART status (Table 1). The K-M curves also show that the longer the patients are on 
ART the lower the TB incidence in all the patient strata (gender, age and CD4 count). 
Associations with TB incidence 
Crude analysis with no covariates showed a 50.5% (95% CI, 49.6% - 51.3%) and 52.5% (95% CI, 
51.7% - 53.3%) reduction in TB incidence associated with ART in the full and lagged dataset 
respectively (Figure 3). While in the crude analysis with baseline covariates, ART was associated 
with a 72.7% (95% CI, 72.2% - 73.2%) and 67.9% (95% CI, 67.3% - 68.5%) reduction in TB 
incidence in the full and lagged dataset respectively (Figure 3).  
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The IPTW marginal structural model (MSM) estimated a 79.6% (95%CI, 79.1% - 80.1%) and 
77.3% (95% CI, 76.7% - 78.0%) reduction in TB incidence associated with ART in the full and 
lagged dataset respectively. These estimates were higher than the unweighted estimates which 
adjusted for baseline covariates, suggesting the presence of time-varying confounding by CD4 
count. Removing the follow-up period during which HIV and TB might have been co-diagnosed 
(the lagged dataset), only slightly attenuated the adjusted estimates of the effect of ART.  
Discussion 
The MSM with IPTW was used to estimate the causal effect of ART on TB incidence among 
people living with HIV adjusting for time-varying confounding. The study has shown that being 
on ART is associated with an 80% and 77% reduced risk of TB in people living with HIV in the 
full and lagged dataset respectively. This clearly shows the importance of ART in patients living 
with HIV in preventing TB disease.  The overall TB incidence was 9 855 and 5 835 per 100 000 
patient years in the full and lagged dataset respectively. TB incidence was higher in men, older 
patients, and was strongly associated with immune deficiency represented by CD4 count and 
increased with an increase in age. 
Effect size compared to previous estimates 
The effect size in our study is slightly greater than estimates from a previous systematic review 
and meta-analysis from developing countries and limited resources settings which noted a 65% 
and 67% reduction in TB incidence associated with ART respectively (Lawn et al., 2010, Suthar 
et al., 2012). It is much greater than the only previous South African study which used similar 
methods and found a 39% reduction, although this study was from a very different period early 
on in the ART programme (Fairall et al., 2008). 
This TB risk reduction estimate is comparable to the estimate found in a similar study in China, 
which showed a 73% reduction of TB incidence associated with ART. However, the effect size 
estimate is much higher than the estimate by del Amo et al (2012) of 44%, which used similar 
methods based on 12 cohorts from high income countries. Other related studies which used 
traditional methods have shown varying estimates, from  73% reduction in Western Cape 
Province, South Africa (Bock et al., 2018), 60% reduction in Ethiopia (Ayele et al., 2015) and 
32% reduction in Gauteng Province, South Africa (Kufa et al., 2016). 
The incidence of TB in South Africa has been noted to have been declining, with the decline 
associated with increased ART coverage (Nanoo et al., 2015), thus this population effect could 
explain the higher effect size in our study in comparison with other studies. 
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Ongoing high incidence of TB in spite of ART 
Despite ART being shown to reduce TB incidence in adult HIV patients in the Western Cape, 
there is continued high TB incidence on average in people on ART (3 939 and 3 645 per 100 000 
patient years in full and lagged datasets respectively), and patients on ART with CD4 count 
greater than 500 (1 114 and 1 106 per 100 000 patient years in full and lagged datasets 
respectively). 
The study also showed a decline in TB incidence with longer duration on ART. This has also 
been evidenced in other studies which have shown a decline in TB incidence the longer patients 
are on ART (Moore et al., 2007, Girardi et al., 2005, Lawn et al., 2005, Brinkhof et al., 2007, 
Lawn et al., 2009).  Hence the early initiation of ART based on the universal test and treat (UTT) 
guidelines in the country is going to reduce the lifetime risk of developing TB in people living 
with HIV. However, other studies have also shown that TB incidence in people living with HIV 
remains higher than the background TB incidence in the general population, even after years of 
being on ART (Lawn et al., 2009, Gupta et al., 2012, Gupta et al., 2015).  
The higher incidence in patients on long term ART and patients on ART with CD4 count 
greater than 500 could be due to long term ART not resulting in immune reconstitution to these 
levels either because of low CD4 count nadir at ART start, or poor retention on ART with 
representation with advanced disease (Sharma and Soneja, 2011, Osler et al., 2018, Darraj et al., 
2018). Use of Isoniazid preventative therapy (IPT) in addition to ART has been noted to be 
significantly associated with reduced TB incidence  (Golub et al., 2007, Rangaka et al., 2014). In 
our study data on IPT uptake were not available, but it is generally considered to be suboptimal. 
Initial high incidence of TB after HIV first evidence 
Within the first few months of HIV first evidence there is simultaneous presentation of TB, 
which is a result of HIV and TB co-diagnosis, making TB incidence very high in this period 
(initially) in both patients off ART and on ART. These incidences are higher in patients off ART, 
and this is probably due patients presenting at health facilities when they are very sick, have low 
CD4 counts and HIV and TB co-diagnosed. This has also been noted in other studies, where 
during the first weeks of HIV diagnosis TB incidence is very high, with risk factors such as low 
CD4 counts,  TB patients diagnosed with HIV after seeking medical treatment for TB, late 
presentation by sick patients, poverty and poor socio-economic status (Kwan and Ernst, 2011, 
Alvarez-Uria et al., 2014). The high incidence of TB in the first months of ART have been 
consistently documented across different regions globally in other studies as well (Van Rie et al., 
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2011, Moore et al., 2007, Girardi et al., 2005, Lawn et al., 2005, Bonnet et al., 2006, Brinkhof et 
al., 2007, Dembele et al., 2010, Rajasekaran et al., 2009). This is attributed to the unmasking of 
subclinical TB during the initial rapid restoration of the immune response (Lawn et al., 2009).  
Strength and weaknesses of the study 
The major strengths of this study in this high HIV and TB burden setting is the better TB 
ascertainment through linkage of provincial TB and HIV registers and electronic laboratory data 
through the provincial health data centre. This made this a population-wide study with high 
levels of outcome ascertainment as they were not only restricted to registered treated TB cases.  
One of the strengths of this study is the representative nature of the data coming from the public 
health sector which accounts for about 95% of HIV and TB patients in the Province, and which 
is thus generalisable to similar populations. 
We also had a large sample (494 871 HIV patients linked to 115 374 TB patients and 441 310 
HIV patients linked to 61 813 TB patients in the full and lagged dataset respectively) size in 
comparison to similar studies, which allowed the association between ART and reduction in TB 
incidence to be estimated more precisely. The marginal structural models used to estimate the 
ART effectiveness in reducing TB incidence helped to control for any possible time-varying 
confounding by CD4 count. 
The limitations of the study include that some clinically diagnosed TB cases could not be linked 
due to insufficient recording of unique patient identifiers especially in the earlier years where 
some were not captured. We did not impute missing CD4 count data (including time-varying 
CD4 count, which was carried forward for a year if missing), which might have introduced bias 
and affected the weighting models. Sensitivity analysis of our models with and without the 
missing CD4 count data did not however show any notable differences in the overall results. A 
further limitation is that clinical characteristics of TB cases have not been incorporated in this 
study and data on IPT was not available to use as well.  
Conclusion 
In summary, our findings demonstrate a substantial reduction in TB incidence in HIV patients 
due to ART regardless of CD4 count, even though the incidence on ART remains high, 
including many years after initiation. 
Funding 
This study was not funded. 
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Tables and Figures 
 
 
Figure 1: Flow diagram of HIV and TB patients included in the study 
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Table 1: Baseline characteristics of HIV cohort and associated TB incidence  
                      N       % 
TB incidence / 
per 100 000 py     95% CI
TB incidence / 
per 100 000 py     95% CI
TB incidence / 
per 100 000 py     95% CI
TB incidence / 
per 100 000 py     95% CI
Total number (N) 494 871 15 329 (15231 : 15427) 3 939 (3888 : 3992) 8 144 (8066 : 8222) 3 645 (3595 : 3696)
Female 321 021 (65%) 11 147 (11049 : 11246) 3 397 (3342 : 3454) 6 801 (6719 : 6885) 3 196 (3141 : 3252)
Male 173 850 (35%) 26 329 (26085 : 26576) 5 432 (5315 : 5551) 11 844 (11664 : 12028) 4 900 (4787 : 5016)
Median age at HIV ascertainment 
Total 31.0 (IQR, 25.6 - 38.1)
Female 29.2 (IQR, 24.3 - 35.9)
Male 34.3 (IQR, 28.8 - 41.1)
Age groups
15-24 110 531 (22.3%) 8 918 (8777 : 9061) 3 529 (3424 : 3638) 6 275 (6149 : 6405) 3 438 (3333 : 3547)
25-34 214 377 (43.3%) 14 286 (14146 : 14428) 3 701 (3628 : 3776) 7 875 (7762 : 7989) 3 450 (3379 : 3524)
35-44 112 373 (22.7%) 22 373 (22102 : 22647) 4 418 (4305 : 4534) 10 319 (10119 : 10524) 3 977 (3868 : 4089)
45-54 42 377 (8.6%) 26 379 (25862 : 26906) 4 797 (4595 : 5008) 11 490 (11113 : 11881) 4 212 (4019 : 4415)
55-64 12 034 (2.4%) 30 771 (29577 : 32014) 4 836 (4412 : 5301) 12 261 (11401 : 13187) 4 330 (3918 : 4785)
65+ 3 177 (0.6%) 31 411 (28734 : 34338) 6 087 (4968 : 7459) 11 761 (9773 : 14154) 5 142 (4088 : 6468)
Year of HIV ascertainment
2007-2010 233 798 (47.2%) 12 801 (12694 : 12909) 3 828 (3763 : 3894) 8 101 (8010 : 8192) 3 715 (3651 : 3780)
2011-2013 138 774 (28.0%) 16 858 (16644 : 17074) 3 930 (3835 : 4028) 7 804 (7644 : 7967) 3 539 (3447 : 3634)
2014-2016 122 299 (24.7%) 36 285 (35708 : 36870) 4 667 (4490 : 4851) 10 514 (10106 : 10939) 3 487 (3321 : 3660)
Median time to ART in months 6.8 (IQR, 1.3 - 31.8)
CD4 count category at HIV ascertainment (cells/µl)
0-49 28 953 (5.9%) 176 109 (172908 : 179368) 7 753 (7414 : 8108) 23 670 (22151 : 25294) 5 665 (5366 : 5980)
50-199 105 703 (21.4%) 51 515 (50918 : 52119) 5 186 (5076 : 5298) 19 110 (18692 : 19537) 4 652 (4546 : 4761)
200-349 125 898 (25.4%) 15 551 (15345 : 15759) 3 473 (3391 : 3557) 10 849 (10662 : 11040) 3 397 (3314 : 3481)
350-499 98 991 (20.0%) 8 572 (8432 : 8714) 2 995 (2892 : 3101) 6 927 (6792 : 7064) 2 976 (2872 : 3083)
500+ 118 560 (24.0%) 5 760 (5664 : 5858) 2 482 (2372 : 2596) 4 830 (4737 : 4926) 2 479 (2369 : 2595)
No CD4 count 16 766 (3.4%) 55 092 (53443 : 56791) 6 818 (5446 : 8537) 25 875 (23817 : 28112) 3 401 (2378 : 4864)
Median CD4 count at HIV ascertainment (cells/µl) 324 (IQR, 182 - 499)
CD4 count category time-varying (cells/µl)
0-49 71 675 (70521 : 72848) 25 765 (24844 : 26721) 21 441 (20765 : 22139) 23 610 (22658 : 24603)
50-199 32 717 (32360 : 33079) 11 942 (11680 : 12211) 13 875 (13625 : 14129) 11 376 (11104 : 11655)
200-349 11 960 (11784 : 12139) 4 279 (4159 : 4402) 6 951 (6806 : 7100) 4 201 (4078 : 4327)
350-499 6 754 (6616 : 6895) 1 953 (1872 : 2037) 4 324 (4204 : 4448) 1 909 (1829 : 1993)
500+ 4 429 (4330 : 4529) 1 114 (1061 : 1170) 2 849 (2763 : 2937) 1 106 (1053 : 1162)
No CD4 count 32 400 (31840 : 32970) 2 467 (2380 : 2557) 26 878 (26329 : 27438) 2 433 (2347 : 2523)
Median CD4 count at ART start (cells/µl) 242 (IQR, 151 - 347)
Full data set 3 months lag
Off ART On ART Off ART On ART
CD4 count baseline CD4 count baseline CD4 count baseline CD4 count baseline
CD4 count time-varying CD4 count time-varying CD4 count time-varying CD4 count time-varying
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Figure 2: Kaplan-Meier failure estimates time to TB, 2007-2016; by ART status, Full 
dataset (A) and 3 months lag (B) and by time-varying CD4 count, Full dataset (C) and 3 
months lag (D) 
 
 
Figure 3: Marginal structural model with inverse probability to weight estimates 
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Supplementary material 
 
Figure 4: TB incidence by gender and CD4 count, full dataset (A), 3 months lag (B) 
 
 
Figure 5: Age distribution of female HIV+ (A), male HIV+ (B), female TB+ (C) and 
male TB+ (D) patients, 2007-2016 
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2 These are based on first TB episodes in HIV-TB co-infected patients 
N % N % N % 
Total number 93 207 22 167 115 374
Female 49 110 (52.7%) 14 025 (63.3%) 63 135 (54.7%)
Male 44 097 (47.3%) 8 142 (36.7%) 52 239 (45.3%)




TB in first 3 months of HIV 51 216 (54.9%) 2 345 (10.6%) 53 561 (46.4%)
Year of TB ascertainment
2007-2010 42 455 (36.8%) 38 727 (41.5%) 3 728 (16.8%)
2011-2013 37 856 (32.8%) 30 064 (32.3%) 7 792 (35.2%)
2014-2016 35 063 (30.4%) 24 416 (26.2%) 10 647 (48.0%)
Treatment status (TB treated)
Evidence of TB treatment 49 893 (53.5%) 11 741 (53.0%) 61 634 (53.4%)
TB characteristics on evidence of treatment
TB classification , N=61 634
Extra-Pulmonary 10 253 (11.0%) 2 880 (13.0%) 13 133 (11.4%)
Pulmonary 41 097 (44.1%) 10 040 (45.3%) 51 137 (44.3%)
Unknown 41 857 (44.9%) 9 247 (41.7%) 51 104 (44.3%)
Microbiological classification, N=61 634
Culture/PCR/GeneXpert positive 31 754 (63.6%) 8 742 (74.5%) 40 496 (65.7%)
Smear positive 14 527 (30.2%) 4 072 (34.7%) 18 599 (30.2%)
TB treatment outcomes, N=61 634
Cured 9 421 (18.9%) 2 126 (18.1%) 11 547 (18.7%)
Died 3 029 (6.1%) 548 (4.7%) 3 577 (5.8%)
Treatment completed 22 857 (45.8%) 5 969 (50.8%) 28 826 (46.8%)
Treatment failure/default/relapse 4 029 (8.1%) 760 (6.5%) 4 789 (7.8%)
Loss-to-follow-up 10 121 (20.3%) 2 259 (19.2%) 12 380 (20.1%)
Drug Resistance
MDR-TB 1 525 (1.6%) 496 (2.2%) 2 021 (1.8%)
Mono/Poly 165 (0.2%) 66 (0.3%) 231 (0.2%)
XDR-TB 69 (0.1%) 36 (0.2%) 105 (0.1%)
30.5   (IQR, 25.2 - 37.6) 29.9   (IQR, 24.9 - 36.5) 30.4   (IQR, 25.1 - 37.4)
35.3   (IQR, 30.0 - 41.6) 35.3   (IQR, 29.9 - 41.7) 35.3   (IQR, 30.0 - 41.7)
On ART Off ART Total
32.9   (IQR, 27.2 - 39.8) 31.9   (IQR, 26.4 - 38.8) 32.7   (IQR, 27.0 - 39.6)
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Figure 6: Kaplan-Meier failure estimates time to TB, 2007-2016; by gender, Full dataset 
(A) and 3 months lag (B) and by year of HIV ascertainment, Full dataset (C) and 3 
months lag (D) 
 
 
Figure 7: Kaplan-Meier failure estimates time to TB by baseline CD4 count, 2007-2016, 
Full dataset (A) and 3 months lag (B) 
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Table 3: MSM with IPTW Models 
 
 
             HR HR (95% CI) p-value              HR HR (95% CI) p-value
Unweighted model, no covariates
ART (reference no ART ) 0.495 (0.487 : 0.504) 0.00 0.475 (0.467 : 0.483) 0.00
constant 0.170 (0.966 : 0.967) 0.00 0.013 (0.012 : 0.014) 0.00
Unweighted model, baseline covariates
ART (reference no ART ) 0.273 (0.268 : 0.278) 0.00 0.321 (0.315 : 0.327) 0.00
CD4 count baseline
0-49 2.922 (2.824 : 3.023) 0.00 0.796 (0.725 : 0.873) 0.00
50-199 1.421 (1.379 : 1.465) 0.00 0.701 (0.645 : 0.762) 0.00
200-349 0.688 (0.667 : 0.710) 0.00 0.474 (0.437 : 0.515) 0.00
350-499 0.455 (0.441 : 0.470) 0.00 0.333 (0.306 : 0.362) 0.00
500+ 0.320 (0.309 : 0.331) 0.00 0.235 (0.216 : 0.255) 0.00
no CD4 1 reference 1.000 reference
Year of HIV ascertainment
2007-2010 0.822 (0.807 : 0.837) 0.00 0.786 (0.759 : 0.814) 0.00
2011-2013 0.896 (0.878 : 0.914) 0.00 0.800 (0.772 : 0.829) 0.00
2014-2016 1 reference 1.000 reference
Age group
15-24 1 reference 0 reference
25-34 1.112 (1.093 : 1.132) 0.00 1.030 (1.008 : 1.052) 0.01
35-44 1.332 (1.307 : 1.358) 0.00 1.182 (1.154 : 1.211) 0.00
45-54 1.458 (1.423 : 1.494) 0.00 1.292 (1.250 : 1.336) 0.00
55-64 1.454 (1.396 : 1.515) 0.00 1.351 (1.270 : 1.438) 0.00
65+ 1.272 (1.167 : 1.387) 0.00 1.319 (1.140 : 1.526) 0.00
Gender_Male (reference female) 1.539 (1.520 : 1.558) 0.00 1.427 (1.403 : 1.452) 0.00
Spline
Spline1 0.971 (0.971 : 0.972) 0.00 0.9970 (0.9966 : 0.9974) 0.00
Spline2 1.003 (1.003 : 1.003) 0.00 1.0006 (1.0005 : 1.0007) 0.00
Spline3 0.9998 (0.9998 : 0.9999) 0.00 0.99996 (0.99994 : 0.99997) 0.00
Spline4 1.00003 (1.00003 : 1.00004) 0.00 1.00002 (1.00001 : 1.00002) 0.00
Spline5 0.99999 (0.99999 : 0.99999) 0.00 0.99999 (0.99999 : 0.999995) 0.00
Spline6 1 reference 0 reference
cummonth 0.502 (0.497 : 0.506) 0.00 0.874 (0.863 : 0.885) 0.00
constant 0.145 (0.140 : 0.150) 0.00 0.033 (0.030 : 0.036) 0.00
Weighted model, baseline covariates
ART (reference no ART ) 0.204 (0.199 : 0.209) 0.00 0.227 (0.220 : 0.233) 0.00
CD4 count baseline
0-49 3.188 (3.074 : 3.305) 0.00 1.093 (0.984 : 1.215) 0.10
50-199 1.499 (1.453 : 1.547) 0.00 0.886 (0.810 : 0.968) 0.01
200-349 0.700 (0.678 : 0.722) 0.00 0.563 (0.516 : 0.615) 0.00
350-499 0.453 (0.438 : 0.469) 0.00 0.377 (0.345 : 0.412) 0.00
500+ 0.312 (0.301 : 0.323) 0.00 0.257 (0.235 : 0.280) 0.00
no CD4 1 reference 1.000 reference
Year of HIV ascertainment
2007-2010 0.764 (0.749 : 0.779) 0.00 0.588 (0.562 : 0.615) 0.00
2011-2013 0.880 (0.862 : 0.899) 0.00 0.693 (0.661 : 0.726) 0.00
2014-2016 1 reference 1.000 reference
Age group
15-24 1 reference 1 reference
25-34 1.106 (1.085 : 1.129) 0.00 1.018 (0.990 : 1.048) 0.21
35-44 1.329 (1.300 : 1.358) 0.00 1.176 (1.138 : 1.215) 0.00
45-54 1.452 (1.412 : 1.493) 0.00 1.285 (1.229 : 1.344) 0.00
55-64 1.475 (1.409 : 1.544) 0.00 1.428 (1.314 : 1.552) 0.00
65+ 1.224 (1.116 : 1.342) 0.00 1.200 (0.996 : 1.446) 0.06
Gender_Male (reference female) 1.499 (1.478 : 1.520) 0.00 1.345 (1.315 : 1.376) 0.00
Spline
Spline1 0.972 (0.972 : 0.973) 0.00 0.997 (0.996 : 0.997) 0.00
Spline2 1.0031 (1.0030 : 1.0032) 0.00 1.001 (1.001 : 1.001) 0.00
Spline3 0.99986 (0.9998 : 0.9999) 0.00 0.99995 (0.99992 : 0.99997) 0.00
Spline4 1.00003 (1.00003 : 1.00004) 0.00 1.00002 (1.00001 : 1.00003) 0.00
Spline5 0.99999 (0.99998 : 0.99999) 0.00 0.99999 (0.99998 : 0.999995) 0.00
Spline6 1 reference 1 reference
cummonth 0.516 (0.511 : 0.522) 0.00 0.863 (0.850 : 0.876) 0.00
constant 0.145 (0.140 : 0.150) 0.00 0.040 (0.036 : 0.045) 0.00
Full dataset 3 months lag
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Table 4: Summary of stabilised weights  
 Full dataset 3 months lag 
Minimum 0.069 0.063 
Maximum 5.111 7.712 
Mean 1.015 1.030 
Std. Dev. 0.843 1.157 
Variance 0.711 1.339 
Skewness 3.688 4.736 
Kurtosis 18.241 27.098 
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